peptide therapy

Over the past year, I’ve seen a marked increase in patients asking about “peptide therapy” promoted by wellness clinics and med spas—particularly for weight loss, muscle building, and anti-aging. What many patients do not realize is that regulatory enforcement and litigation in this space are accelerating rapidly.

Federal and state authorities are targeting the unauthorized sale, misbranding, and unsafe compounding of peptide-based products. The FDA has intensified scrutiny of companies marketing unapproved or imported peptides—often labeled as “research chemicals” but clearly intended for human use. State medical boards and attorneys general are also investigating clinics promoting these substances without proper regulatory footing.

Compounding pharmacies face heightened exposure. Enforcement actions are focusing on the use of non–FDA-approved bulk ingredients in compounded formulations, including versions of semaglutide and tirzepatide. The statutory framework for compounding is narrow. When pharmacies operate outside those guardrails, patient safety and legal liability intersect.

The FDA has identified multiple peptide substances as presenting potential significant safety risks or lacking adequate safety data. Concerns include immunogenicity, peptide impurities, aggregation risk, and documented adverse events. We are also seeing civil penalties for false advertising and, in some cases, criminal charges involving fraud and interstate misbranding.

The ripple effect is significant.

Pharmacies face audits, supply disruptions, and compliance costs. Clinics may abruptly lose access to products. Patients experience treatment interruptions—or exposure to improperly dosed or contaminated compounds. When oversight fails upstream, consequences appear downstream—in exam rooms and courtrooms.

Innovation in medicine is essential. But innovation without scientific validation and regulatory compliance becomes risk.

For law firms handling matters involving FDA regulation, compounding pharmacy compliance, pharmaceutical misbranding, or standard-of-care disputes related to peptide therapies, this is an increasingly complex and litigated area.

I am available to serve as an expert witness or consultant in cases involving:

• FDA regulatory standards and compounding law

• Pharmaceutical safety and labeling issues

• Medical standard of care

• Causation analysis in adverse event claims

As a board-certified plastic surgeon and PhD-trained scientist, I bring clinical and regulatory insight to complex medico-legal matters.

If your firm is handling cases in this domain, I welcome a confidential discussion.